Drug control and formulary management in Malaysia.

نویسنده

  • Samsinah H Hussain
چکیده

From the year 2000, the national drug expenditure has seen an increase from RM346 million ($91 million) to RM915 million ($241 million) in 2005. From the year 2004 to 2005, an increase of 13.3% was recorded [1]. Factors that may contribute to this increase include increase in drug prices, a growing and aging population, higher expectation of the public regarding equality in assessing therapy, long-term drug treatment and polypharmacy, improvements in diagnosis and treatment of diseases, and technological advancement that produces newer expensive drugs [2,3].

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cost-Containment of Non-Formulary Medicines Accessibility: Malaysian Experience

Methods This study was designed to assess and review current practice and policy in the Malaysia pharmaceutical procurement procedures of non-formulary medicines. This was a quantitative study and was conducted in a cross-sectional study design. A purposive sampling method was applied in the study sample selection. The targeted samples to be involved in the selection were the public healthcare ...

متن کامل

Evaluating the appropriate use of piperacillin/tazobactam in a community health system: a retrospective chart review.

Noting inappropriate uses of piperacillin/tazobactam at their institution, the authors emphasize the need for antimicrobial stewardship efforts, as well as infection-control practices, to curtail drug resistance, reduce costs, and minimize adverse events.

متن کامل

National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool

PURPOSE HMG-CoA reductase inhibitors (statins) are extensively used in treating hypercholesterolemia. The statins available in Malaysia include atorvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and fluvastatin. Over the years, they have accumulated in the National Drug Formulary; hence, the need for review. Effective selection of the best drugs to remain in the formulary can bec...

متن کامل

Talk of a "Default" Drug Formulary Rattles Industry: CMS Could Move in That Direction for Marketplace Plans After 2019, but the Discussion Has Already Started.

A proposed CMS rule promising to consider a federal default prescription drug benefit after 2019 has startled manufacturers, pharmacy benefit managers, P&T committees, and pharmacies alike. We consider the rationale and potential effects of such a rule.

متن کامل

Part d changes for 2013 will put pressure on p&t committees: drug utilization reviews and medication therapy management programs under the gun.

In the Call Letter, CMS encourages ACOs to find Part D plan sponsor partners through a request for proposal process. I do believe that ACOs have an incentive to work with PDPs to control medical costs, including preventing readmissions. However, ACOs have no incentive to work to appropriately manage Part D utilization and may have incentives to increase Part D utilization to prevent the use of ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

دوره 11 Suppl 1  شماره 

صفحات  -

تاریخ انتشار 2008